These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 34207212)

  • 21. Implants for HIV prevention in young women: Provider perceptions and lessons learned from contraceptive implant provision.
    Humphries H; Upfold M; Mahlase G; Mdladla M; Gengiah TN; Abdool Karim Q
    PLoS One; 2022; 17(1):e0262043. PubMed ID: 35025908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates.
    Pons-Faudoa FP; Di Trani N; Capuani S; Hernandez N; Wood AM; Nehete B; Niles J; Shelton KA; Kezar S; Bushman LR; Chua CYX; Ittmann MM; Anderson PL; Nehete PN; Arduino RC; Nichols JE; Grattoni A
    J Control Release; 2023 Jun; 358():116-127. PubMed ID: 37120032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design of an Implant for Long-Acting HIV Pre-Exposure Prophylaxis: Input from South African Health Care Providers.
    Krogstad EA; Montgomery ET; Atujuna M; Minnis AM; O'Rourke S; Ahmed K; Bekker LG; van der Straten A
    AIDS Patient Care STDS; 2019 Apr; 33(4):157-166. PubMed ID: 30932697
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges.
    Agrahari V; Anderson SM; Peet MM; Wong AP; Singh ON; Doncel GF; Clark MR
    Expert Opin Drug Deliv; 2022 Oct; 19(10):1365-1380. PubMed ID: 36252277
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulation of biodegradability and drug release behavior of aliphatic polyesters by blending.
    Shen Y; Sun W; Zhu KJ; Shen Z
    J Biomed Mater Res; 2000 Jun; 50(4):528-35. PubMed ID: 10756311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A New Approach to Developing Long-Acting Injectable Formulations of Anti-HIV Drugs: Poly(Ethylene Phosphoric Acid) Block Copolymers Increase the Efficiency of Tenofovir against HIV-1 in MT-4 Cells.
    Nifant'ev I; Siniavin A; Karamov E; Kosarev M; Kovalchuk S; Turgiev A; Nametkin S; Bagrov V; Tavtorkin A; Ivchenko P
    Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396968
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting.
    Romano JW; Baum MM; Demkovich ZR; Diana F; Dobard C; Feldman PL; Garcia-Lerma JG; Grattoni A; Gunawardana M; Ho DK; Hope TJ; Massud I; Milad M; Moss JA; Pons-Faudoa FP; Roller S; van der Straten A; Srinivasan S; Veazey RS; Zane D
    AIDS Res Hum Retroviruses; 2021 Jun; 37(6):409-420. PubMed ID: 33913760
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of hot-melt extruded drug/polymer matrices for sustained delivery of meloxicam.
    Chen YC; Moseson DE; Richard CA; Swinney MR; Horava SD; Oucherif KA; Cox AL; Hawkins ED; Li Y; DeNeve DF; Lomeo J; Zhu A; Lyle LT; Munson EJ; Taylor LS; Park K; Yeo Y
    J Control Release; 2022 Feb; 342():189-200. PubMed ID: 34990702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
    Krakower DS; Mayer KH
    Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
    Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
    Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
    Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Electrospun fibers for vaginal administration of tenofovir disoproxil fumarate and emtricitabine in the context of topical pre-exposure prophylaxis.
    Nunes R; Bogas S; Faria MJ; Gonçalves H; Lúcio M; Viseu T; Sarmento B; das Neves J
    J Control Release; 2021 Jun; 334():453-462. PubMed ID: 33961916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparative Pricing of Branded Tenofovir Alafenamide-Emtricitabine Relative to Generic Tenofovir Disoproxil Fumarate-Emtricitabine for HIV Preexposure Prophylaxis: A Cost-Effectiveness Analysis.
    Walensky RP; Horn T; McCann NC; Freedberg KA; Paltiel AD
    Ann Intern Med; 2020 May; 172(9):583-590. PubMed ID: 32150602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Formulation, characterization, and evaluation of ketorolac tromethamine-loaded biodegradable microspheres.
    Sinha VR; Trehan A
    Drug Deliv; 2005; 12(3):133-9. PubMed ID: 16025842
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Controlled release of metronidazole from composite poly-ε-caprolactone/alginate (PCL/alginate) rings for dental implants.
    Lan SF; Kehinde T; Zhang X; Khajotia S; Schmidtke DW; Starly B
    Dent Mater; 2013 Jun; 29(6):656-65. PubMed ID: 23602170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CAPRISA 018: a phase I/II clinical trial study protocol to assess the safety, acceptability, tolerability and pharmacokinetics of a sustained-release tenofovir alafenamide subdermal implant for HIV prevention in women.
    Gengiah TN; Abdool Karim Q; Harkoo I; Mansoor L; Zuma NY; Radebe P; Samsunder N; Baxter C; Maharaj B; Baum MM; Moss JA; Pozzetto B; Hankins C; Abdool Karim S
    BMJ Open; 2022 Jan; 12(1):e052880. PubMed ID: 34992111
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques.
    Su JT; Simpson SM; Sung S; Tfaily EB; Veazey R; Marzinke M; Qiu J; Watrous D; Widanapathirana L; Pearson E; Peet MM; Karunakaran D; Grasperge B; Dobek G; Cain CM; Hope T; Kiser PF
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871073
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Feasibility of poly (ϵ-caprolactone-co-DL-lactide) as a biodegradable material for in situ forming implants: evaluation of drug release and in vivo degradation.
    Zhang X; Zhang C; Zhang W; Meng S; Liu D; Wang P; Guo J; Li J; Guan Y; Yang D
    Drug Dev Ind Pharm; 2015 Feb; 41(2):342-52. PubMed ID: 24320881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A poly(ε-caprolactone) device for sustained release of an anti-glaucoma drug.
    Natu MV; Gaspar MN; Ribeiro CA; Correia IJ; Silva D; de Sousa HC; Gil MH
    Biomed Mater; 2011 Apr; 6(2):025003. PubMed ID: 21293056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Understanding the Acceptability of Subdermal Implants as a Possible New HIV Prevention Method: Multi-Stage Mixed Methods Study.
    Rael CT; Lentz C; Carballo-Diéguez A; Giguere R; Dolezal C; Feller D; D'Aquila RT; Hope TJ
    J Med Internet Res; 2020 Jul; 22(7):e16904. PubMed ID: 32348277
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.